Shares of Lexicon Pharmaceuticals (LXRX) have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk (NVO) last week.Per the deal terms, Lexicon will complete certain preclinical activities before Novo Nordisk takes over the development, manufacturing and commercialization of LX9851. NVO will also be responsible for LX9851’s investigational new drug (IND) filing.In return, LXRX is eligible to receive $75 million as an upfront payment from NVO. Inclu ...

Group 1 - Lexicon Pharmaceuticals will participate in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, at 8:00 a.m. ET [1] - The presentation will be accessible live and via replay on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The Genome5000™ program has enabled Lexicon to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [2] - The company has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-0 ...

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mis ...

Fourth Quarter and Full Year 2024 Earnings Presentation March 2025 1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadi ...

Financial Data and Key Metrics Changes - Lexicon Pharmaceuticals ended 2024 with $238 million in cash, cash equivalents, and short-term investments, compared to $170 million as of December 31, 2023 [28] - The company reported $26.6 million in revenue for Q4 2024 and $31.1 million for the full year 2024, including a $25 million upfront payment from the Beatrice licensing agreement [28] - Research and development expenses for Q4 2024 increased to $26.7 million from $14.8 million in Q4 2023, while full-year R&D expenses decreased to $84.5 million from $106 million in 2023 [29] - Net loss for Q4 2024 was $33.8 million, or $0.09 per share, compared to a net loss of $49.8 million, or $0.20 per share, in Q4 2023 [31] Business Line Data and Key Metrics Changes - The PROGRESS Phase 2b study of pilabapatin showed a clear separation in Average Daily Pain Score (ADPS) from baseline, with the 10-milligram dose demonstrating meaningful improvement compared to placebo [11][14] - The Sonata Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy (HCM) is ongoing, with patient enrollment proceeding as planned [10] Market Data and Key Metrics Changes - Diabetic peripheral neuropathic pain (DPNP) affects approximately nine million people in the US, indicating a significant market opportunity for new treatment options [17] - Current treatments for DPNP are inadequate, with about 60% of patients having tried multiple therapies and only a third being somewhat satisfied with their treatment [19] Company Strategy and Development Direction - Lexicon Pharmaceuticals has strategically repositioned to focus on clinical development programs, including advancing IND enabling studies for LX9851, an oral ACSL5 inhibitor for obesity [10][21] - The company aims to enhance its clinical and commercial capabilities through partnership discussions, particularly for its novel therapies [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of pilabapatin to be the first novel oral, non-opioid DPN medication in over two decades, with plans to advance the 10-milligram dose into pivotal trials [14][16] - The company anticipates total operating expenses for 2025 to be in the range of $135 million to $145 million, with R&D expenses projected between $100 million to $105 million [33] Other Important Information - Lexicon Pharmaceuticals has ceased all promotion of Impepper in the U.S. heart failure market due to a challenging market access environment [24] - The company is actively working with Beatrice on registration and regional development efforts for sotagliflozin outside the U.S. and Europe [25] Q&A Session Summary Question: What is the clinical development plan for LX9851? - Management sees LX9851 being developed as both monotherapy and combination therapy, with a standard Phase 1 program focusing on weight loss, tolerability, and mechanistic differentiation from GLP-1 [42][44][48] Question: How is enrollment progressing in the HCM study? - Enrollment is on track with approximately 500 patients targeted, and final study results are expected towards the end of 2026, with an FDA filing anticipated in Q1 2027 [54][56] Question: Will the Phase 2b data support pivotal trial status? - The current assumption is that the Phase 2b trial will not be considered pivotal, with plans for two pivotal trials in the Phase 3 program [76] Question: What are the commercialization plans for sotagliflozin? - The company plans to commercialize sotagliflozin in the U.S. while seeking a partner for Europe, focusing on centers of excellence for HCM patients [84][86]

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.18%. A quarter ago, it was expected that this drugmaker would post a loss of $0.17 per share when it actually produced a loss of $0.18, delivering a surprise of -5.88%.Over the last four quarters, the company ha ...

Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET The Woodlands, Texas, March 6, 2025 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for th ...

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate milestones and acc ...